Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).

Trial Details

NCT ID

NCT06228482

Phase

PHASE1

Sponsor

University of California, Davis

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.

Locations (sample)

Sacramento, California, United States|38.58157,-121.4944

Key Eligibility Criteria

\[68Ga\]Ga DOTA-5G PET/CT Inclusion Criteria:
Ability to understand and willingness to sign a written informed consent document.
Age 18 or more years
Pathologically confirmed NSCLC with metastatic disease and measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion \> 1 cm or lymph nod…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →